Neal D. Shore, MD

Articles

ARPI-Based Combination Regimens – CONTACT-02 (Cabozantinib plus atezolizumab)

October 28th 2024

Panelists discuss how the CONTACT-02 trial highlights the potential of cabozantinib combined with atezolizumab in improving treatment outcomes for patients with advanced cancer.

ARPI-Based Combination Regimens – SPLASH (177 Lu-PNT-2002)

October 28th 2024

Panelists discuss how the SPLASH trial investigating 177Lu-PNT2002 demonstrates promising efficacy in treating advanced cancer through targeted radionuclide therapy.

Key Takeaways and Looking Ahead

October 28th 2024

Panelists discuss how recent advancements in targeted therapies and a multidisciplinary approach can significantly enhance the management and care of patients with metastatic prostate cancer.

Use of Bone Protection Agents

October 21st 2024

Panelists discuss how the PEACE-3 trial explores the efficacy of combining radium-223 with enzalutamide in advanced prostate cancer, highlighting its potential to enhance therapeutic outcomes and survival rates.

ARPI-Based Combination Regimens – ARANOTE (Darolutamide and ADT)

October 21st 2024

Panelists discuss how the ARANOTE trial exploring darolutamide in combination with androgen deprivation therapy shows potential benefits in managing advanced prostate cancer.

Genetic Testing – Somatic

October 14th 2024

Panelists discuss how somatic genetic testing is essential for identifying actionable mutations in prostate cancer, guiding targeted therapies, and improving treatment outcomes for patients.

ARPI-Based Combination Regimens – PEACE-3 (Radium-223 and enzalutamide)

October 14th 2024

Genetic Testing – Germline

October 7th 2024

Panelists discuss how genetic testing for germline mutations is becoming increasingly crucial in the management of prostate cancer, enabling personalized treatment approaches and informing patient care decisions.

Recent Data on ARPI-Based Combination Regimens

October 7th 2024

Panelists discuss how recent data on androgen receptor pathway inhibitor–based combination regimens highlight their potential to enhance treatment outcomes for advanced prostate cancer, underscoring the importance of integrating these findings into clinical practice.

Treatment Timelines Related to Disease State and Use of Monotherapy

September 30th 2024

Panelists discuss the current treatment landscape for metastatic castration-sensitive prostate cancer (mHSPC), exploring main therapeutic approaches, the role of androgen deprivation monotherapy, the timing for adding chemotherapy and ARPIs, and strategies for sequencing or combining these modalities in clinical practice.

Treatment Landscape and Sequencing of Therapies

September 30th 2024

Panelists discuss how advancements in biomarker and genetic testing, along with updated treatment guidelines, are transforming the diagnosis and management of prostate cancer, emphasizing the importance of personalized approaches in optimizing patient outcomes.

Dr Shore on Ongoing Research With Radioligand Therapy in nmCSPC

March 1st 2024

Neal Shore, MD, FACS, discusses current and ongoing research with radioligand therapy in patients with nonmetastatic castration-sensitive prostate cancer.

Dr. Shore on the Long-term Safety of Darolutamide in nmCRPC

March 1st 2023

Neal Shore, MD, FACS, US discusses the continued evaluation of darolutamide in patients with non-metastatic castration-resistant prostate cancer.

Dr. Shore on the Rationale for the Phase 2 ENACT Trial in Prostate Cancer

December 8th 2021

Neal D. Shore, MD, FACS, discusses the rationale for the open-label, randomized phase 2 ENACT trial in prostate cancer.

Dr. Shore on the Utility of PSMA PET Imaging Agent Piflufolastat F 18 for Prostate Cancer

August 23rd 2021

Neal D. Shore, MD, FACS, medical director of the Carolina Urologic Research Center, discusses the clinical utility of piflufolastat F 18 in identifying suspected metastasis or recurrence of prostate cancer.

Dr. Shore on the Design of the ARAMIS Trial With Darolutamide in nmCRPC

June 24th 2021

Neal D. Shore, MD, FACS, discusses the design of the phase 3 ARAMIS trial in nonmetastatic castration-resistant prostate cancer.

Dr. Shore on Future Research Directions with Darolutamide in Prostate Cancer

April 1st 2021

Neal D. Shore, MD, FACS, discusses future research directions with darolutamide for the treatment of patients with prostate cancer.

Dr. Shore on the Objective of the HERO Trial in Advanced Prostate Cancer

September 23rd 2020

Neal D. Shore, MD, FACS, discusses the objective of the phase 3 HERO trial in advanced prostate cancer.

Dr. Shore on Challenges with ADT in Recurrent Prostate Cancer

August 4th 2020

Neal D. Shore, MD, FACS, discusses challenges with androgen deprivation therapy in recurrent prostate cancer.

Dr. Shore on the Tolerability of Darolutamide in Nonmetastatic CRPC

July 20th 2020

Neal D. Shore, MD, FACS, discusses the safety and tolerability benefits of darolutamide in men with nonmetastatic castration resistant prostate cancer.